Insider Selling: Oscar Health (NYSE:OSCR) Director Sells $988,221.90 in Stock

Oscar Health, Inc. (NYSE:OSCR) Director Mario Schlosser sold 31,422 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total value of $988,221.90. Following the transaction, the director owned 449,444 shares in the company, valued at $14,135,013.80. The trade was a 6.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mario Schlosser also recently made the following trade(s):

• On Friday, August 28th, Mario Schlosser sold 150,000 shares of Oscar Health stock. The stock was sold at an average price of $30.79, for a total transaction of $4,618,500.00.
• On Thursday, August 27th, Mario Schlosser sold 600,000 shares of Oscar Health stock. The shares were sold at an average price of $30.34, for a total transaction of $18,204,000.00.
• On Tuesday, June 23rd, Mario Schlosser sold 147,500 shares of Oscar Health stock. The stock was sold at an average price of $29.38, for a total transaction of $4,333,550.00.
• On Tuesday, June 23rd, Mario Schlosser sold 880,000 shares of Oscar Health stock. The stock was sold at an average price of $29.38, for a total transaction of $25,854,400.00.

Oscar Health Trading Up 2.4%

NYSE:OSCR opened at $32.53 on Friday. Oscar Health, Inc. has a 12 month low of $10.69 and a 12 month high of $33.55. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $10.04 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 0.65 and a beta of 2.37. The firm has a fifty day simple moving average of $30.58 and a two-hundred day simple moving average of $23.27.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.70. The firm had revenue of $4.88 billion for the quarter, compared to analyst estimates of $4.73 billion. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The business’s quarterly revenue was up 70.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.89) earnings per share. Analysts expect that Oscar Health, Inc. will post 1.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Oscar Health

Large investors have recently made changes to their positions in the business. Thrive Capital Management LLC grew its position in Oscar Health by 33.4% during the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock valued at $85,258,000 after buying an additional 1,588,395 shares during the period. Baird Financial Group Inc. bought a new stake in Oscar Health in the first quarter worth about $159,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Oscar Health by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 215,650 shares of the company’s stock worth $2,827,000 after acquiring an additional 8,879 shares during the period. Jones Financial Companies Lllp boosted its stake in Oscar Health by 7,473.3% in the first quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after acquiring an additional 2,242 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Oscar Health by 39.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,590 shares of the company’s stock valued at $6,169,000 after acquiring an additional 132,149 shares during the last quarter. 75.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OSCR has been the subject of a number of research reports. UBS Group raised their price objective on Oscar Health from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Robert W. Baird set a $27.00 target price on Oscar Health in a research report on Friday, August 7th. Wall Street Zen upgraded Oscar Health from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 14th. The Goldman Sachs Group restated a “neutral” rating and set a $30.00 price target on shares of Oscar Health in a research note on Tuesday, August 11th. Finally, Barclays upped their price objective on shares of Oscar Health from $35.00 to $39.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Oscar Health presently has a consensus rating of “Hold” and a consensus price target of $26.22.

Oscar Health Company Profile

Oscar Health, Inc is a technology-focused health insurance company that offers health plans and related services to individuals, families and small businesses in the United States. The company’s primary business is providing Individual and Family plans through the Affordable Care Act marketplaces, along with health insurance options for small-group employers in select markets.

Oscar combines insurance coverage with digital tools designed to help members manage their care. Its offerings include online and mobile enrollment, virtual care, provider search and navigation services, claims and benefits information, and access to care teams.